Morgan Stanley
TRDA icon

Morgan Stanley’s Entrada Therapeutics TRDA Stock Holding History

Morgan Stanley’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.22M Sell
176,126
-84,125
-32% -$964K ﹤0.01% 4701
2025
Q4 		$2.68M Sell
260,251
-86,505
-25% -$729K ﹤0.01% 4607
2025
Q3 		$2.01M Buy
346,756
+183,659
+113% +$1.07M ﹤0.01% 4779
2025
Q2 		$1.1M Buy
163,097
+89,436
+121% +$720K ﹤0.01% 5049
2025
Q1 		$666K Sell
73,661
-8,212
-10% -$102K ﹤0.01% 5198
2024
Q4 		$1.42M Sell
81,873
-11,393
-12% -$206K ﹤0.01% 4917
2024
Q3 		$1.49M Buy
93,266
+44,215
+90% +$697K ﹤0.01% 4818
2024
Q2 		$699K Sell
49,051
-58,511
-54% -$832K ﹤0.01% 5145
2024
Q1 		$1.52M Buy
107,562
+8,954
+9% +$127K ﹤0.01% 4724
2023
Q4 		$1.49M Buy
98,608
+77,662
+371% +$1.15M ﹤0.01% 5107
2023
Q3 		$331K Sell
20,946
-8,957
-30% -$141K ﹤0.01% 5342
2023
Q2 		$453K Sell
29,903
-11,865
-28% -$163K ﹤0.01% 5264
2023
Q1 		$606K Buy
41,768
+16,882
+68% +$225K ﹤0.01% 5142
2022
Q4 		$336K Buy
24,886
+14,356
+136% +$252K ﹤0.01% 5435
2022
Q3 		$166K Sell
10,530
-10,655
-50% -$135K ﹤0.01% 5818
2022
Q2 		$258K Buy
21,185
+12,824
+153% +$97.3K ﹤0.01% 5768
2022
Q1 		$78K Buy
8,361
+4,199
+101% +$45K ﹤0.01% 6470
2021
Q4 		$71K Buy
+4,162
New +$101K ﹤0.01% 6632

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley's TRDA Position: Q1 2026 in Review

Morgan Stanley reduced its Entrada Therapeutics (TRDA) stake by 32% in Q1 2026, selling an estimated $964K and leaving 176,126 shares worth $2.22M. The position accounts for ﹤0.01% of the portfolio, ranked #4701.

Morgan Stanley first reported a position in TRDA in Q4 2021 and has held it in 18 quarters since. The position peaked at $2.68M in Q4 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Morgan Stanley held 176,126 shares of Entrada Therapeutics worth $2.22M as of Q1 2026.
  • Morgan Stanley sold 84,125 Entrada Therapeutics shares in Q1 2026, an estimated $964K.
  • Entrada Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4701 holding.
  • Morgan Stanley first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Morgan Stanley's Entrada Therapeutics position peaked at $2.68M in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.